The hemophilia market is a challenging and competitive field but Sanofi is confident that fitusiran, which has just been given the green light by the US Food and Drug Administration (28 March), has the potential to change the disease landscape thanks to the therapy’s effective bleed protection, infrequent dosing and easy administration.
Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
More from Interviews
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.